Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 276 No 7394 p372
1 April 2006

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Low volume dispensing pharmacies still on agenda

Oxygen cylinder headsets

Compensation for redundant oxygen cylinder headsets will start in July

Community pharmacies in England that dispense few prescriptions have been thrown a lifeline by the Pharmaceutical Services Negotiating Committee.

PSNC chief executive Sue Sharpe said at last week’s local pharmaceutical committees ‘conference that low volume dispensing contractors were “still on the agenda”. They had been discussed at the most recent meeting of the PSNC’s funding and contract subcommittee. The committee decided to consider the matter in a year’s time to ensure that the PSNC was ready to decide what to do in the final year of the protected funding that had been agreed as part of the new contract.

Mrs Sharpe also revealed that Department of Health data indicate that around 260 independently owned pharmacies will dispense between 1,100 and 2,000 items monthly in 2006–07. This number will, she said, include many but not all essential small pharmacies, of which there will be around 230. From these figures, the PSNC estimates there are likely to be fewer than 100 independent pharmacies dispensing 1,100–2,000 items monthly.

LPC representatives were also told that pharmacies that supplied oxygen would be compensated for cylinder headsets that were decommissioned as a result of the new home oxygen service.

PSNC head of information services Lindsay McClure said that the DoH had set aside some money that will be paid during July and August. She added that the DoH had asked for details of the cost of other redundant assets, such as delivery vehicles and storage sheds. On the possibility of exit payments, Miss McClure said that the DoH was conscious that the oxygen service could return to crisis if pharmacy contractors stopped delivering oxygen. The fees that pharmacies received were under consideration as part of the development of regional exit plans for contractors.

Back to Top


©The Pharmaceutical Journal